E
SLDB icon

Ergoteles’s Solid Biosciences SLDB Stock Holding History

Ergoteles’s Portfolio SLDB Stock Details SLDB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-13,618
Closed -$95K – 1844
2022
Q3 		$95K Sell
13,618
-3,442
-20% -$34.7K ﹤0.01% 1395
2022
Q2 		$158K Buy
+17,060
New +$177K ﹤0.01% 1403

Other funds holding SLDB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CCM
CAAS Capital Management New York $934M AUM 1.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ergoteles's SLDB Position: Q4 2022 in Review

Ergoteles sold out of Solid Biosciences (SLDB) in Q4 2022, closing a stake of 13,618 shares — an estimated $95K sold.

Ergoteles first reported a position in SLDB in Q2 2022 and held it in 2 quarters. The position peaked at $158K in Q2 2022. 35 funds tracked by Wall St. Rank hold SLDB as of Q4 2022.

  • Ergoteles reported no remaining Solid Biosciences position as of Q4 2022 after selling out during the quarter.
  • Ergoteles sold 13,618 Solid Biosciences shares in Q4 2022, an estimated $95K.
  • Ergoteles first reported a position in Solid Biosciences in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Solid Biosciences position peaked at $158K in Q2 2022.
  • 35 funds tracked by Wall St. Rank held Solid Biosciences as of Q4 2022.

Based on Ergoteles's 13F filing for Q4 2022, filed 14 Feb 2023.